Alt5 Sigma Corporation
11/26/2024 | Press release | Distributed by Public on 11/26/2024 11:56
Material Event Form 8 K
Item 8.01 Other Events.
On November 19, 2024, ALT5 Sigma Corporation ("ALT5") signed a non-binding term sheet with Dr. Amol Soin, sole member of Soin Bioscience LLC ("Soin Bio"), a pharmaceutical development company ("Soin Bio"), relating to the proposed acquisition of Soin Bio by Alyea Therapeutics Corporation ("Alyea"), a wholly-owned subsidiary of ALT5. This acquisition would be part of Alyea's pipeline for pain management pharmaceutical development. ALT5 had previously announced plans to separate its biotech business from its fintech business in the first half of 2025. The proposed acquisition, which includes Soin Bio's innovative "clear patch" pain medication technology, will support Alyea's mission to become a leader in the development of non-addictive pain medications.
Soin Bio's clear patch technology is designed to be applied to any area of pain, similar to a gel, which then dries to function as a pain patch. It is designed to provide continuous delivery of pain medication for up to eight hours, allowing for customized treatment over the targeted area. Unlike conventional pain patches, Soin Bio's patch is clear, invisible, and can be applied over difficult areas, such as joints or body creases. Additionally, it is not water-soluble, ensuring it remains effective even if the area becomes moist. The Soin Bio clear patch technology is still in the investigational stage and is pending clinical trials before FDA approval and market launch.
The letter of intent is the first step in the anticipated acquisition process. The closing of the transaction is subject to a satisfactory due diligence review, tax-related structuring, the preparation and execution of definitive acquisition agreements, and other usual and customary closing conditions for transactions of this scope and magnitude.
Section 9 - Financial Statements and Exhibits